Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors - The prospective pravastatin pooling project
Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors - The prospective pravastatin pooling project
复制标题
DOI：
10.1161/01.cir.102.16.1893
复制
发表时间：
2000-10-17
期刊：
影响因子：
37.8
通讯作者：
Furberg, CD
中科院分区：
文献类型：
--
作者：
Sacks, FM;Tonkin, AM;Furberg, CD
背景：在具有不同基线特征的患者亚组中，先前的试验没有足够的冠状动脉事件数量来明确说明脂质修饰治疗对冠心病的影响。方法和结果：采用前瞻性定义的方案，对3项大型普伐他汀40mg随机试验的数据进行汇总和分析。纳入了19768例患者，102 559人年的随访，2194个主要终点（冠状动脉死亡或非致死性心肌梗死）和3717个扩展终点（主要终点，CABG或PTCA）。普伐他汀显著降低年轻(
Background-Previous trials have had insufficient numbers of coronary events to address definitively the effect of lipid-modifying therapy on coronary heart disease in subgroups of patients with varying baseline characteristics.Methods and Results-The data from 3 large randomized trials with pravastatin 40 mg were pooled and analyzed with the use of a prospectively defined protocol. Included were 19 768 patients, 102 559 person-years of follow-up, 2194 primary end points (coronary death or nonfatal myocardial infarction), and 3717 expanded end points (primary end point, CABG, or PTCA). Pravastatin significantly reduced relative risk in younger (